HIV tissue reservoirs: current advances in research
K Li, B Liu, R Ma, Q Zhang - AIDS patient care and STDs, 2023 - liebertpub.com
Acquired immunodeficiency syndrome (AIDS), caused by the human immunodeficiency
virus (HIV), has become a heavy burden of disease and an important public health problem …
virus (HIV), has become a heavy burden of disease and an important public health problem …
Drug resistance profile among HIV-1 infections experiencing ART with low-level viral load in Guangdong China during 2011–2022: A retrospective study
Y Lan, X Ling, X Deng, Y Lin, J Li, L Li… - Infection and Drug …, 2023 - Taylor & Francis
Background Antiretroviral therapy (ART) efficiently reduces the morbidities and mortalities
caused by HIV-1 infection and prevents the HIV epidemic. However, virologic failure (VF) …
caused by HIV-1 infection and prevents the HIV epidemic. However, virologic failure (VF) …
Changes to inflammatory markers during 5 years of viral suppression and during viral blips in people with HIV initiating different integrase inhibitor based regimens
NT Funderburg, SSY Huang, C Cohen… - Frontiers in …, 2024 - frontiersin.org
Background Heightened levels of inflammatory markers are linked to increased
morbidity/mortality in people with HIV (PWH) and often remain elevated after virologic …
morbidity/mortality in people with HIV (PWH) and often remain elevated after virologic …
Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV
J Ouyang, J Yan, X Zhou, S Isnard… - Frontiers in …, 2023 - frontiersin.org
The intestinal barrier has the daunting task of allowing nutrient absorption while limiting the
entry of microbial products into the systemic circulation. HIV infection disrupts the intestinal …
entry of microbial products into the systemic circulation. HIV infection disrupts the intestinal …
CD8 lymphocytes mitigate HIV-1 persistence in lymph node follicular helper T cells during hyperacute-treated infection
OO Baiyegunhi, J Mann, T Khaba, T Nkosi… - Nature …, 2022 - nature.com
HIV persistence in tissue sites despite ART is a major barrier to HIV cure. Detailed studies of
HIV-infected cells and immune responses in native lymph node tissue environment is critical …
HIV-infected cells and immune responses in native lymph node tissue environment is critical …
Symptomatic and asymptomatic neurocognitive impairment, ART adherence and HIV control: a 4-year observational study
M Trunfio, E Vuaran, D Vai, C Quarta, A Di Stefano… - AIDS and Behavior, 2024 - Springer
We assessed whether symptomatic neurocognitive impairment (NCI) and asymptomatic NCI-
of which the clinical relevance is debated-affect HIV control and the role of ART adherence …
of which the clinical relevance is debated-affect HIV control and the role of ART adherence …
Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya
A Aoko, S Pals, T Ngugi, E Katiku, R Joseph… - …, 2023 - thelancet.com
Background HIV low-level viremia (LLV)(51–999 copies/mL) can progress to treatment
failure and increase potential for drug resistance. We analyzed retrospective longitudinal …
failure and increase potential for drug resistance. We analyzed retrospective longitudinal …
Curcumin enhances elvitegravir concentration and alleviates oxidative stress and inflammatory response
In this study, we investigated the potential of using curcumin (CUR) as an adjuvant to
enhance the delivery of antiretroviral drug elvitegravir (EVG) across the BBB, and alleviate …
enhance the delivery of antiretroviral drug elvitegravir (EVG) across the BBB, and alleviate …
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case–Control Study
F Lombardi, E Bruzzesi, YR Bouba… - AIDS Research and …, 2024 - liebertpub.com
Despite effective antiretroviral therapies (ARTs), a subset of people living with HIV (PLWH)
still experience low-level viremia (LLV, ie, 50–1,000 copies/mL). The present study …
still experience low-level viremia (LLV, ie, 50–1,000 copies/mL). The present study …
Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy: a Swedish observational study
H Brattgård, P Björkman, P Nowak, CJ Treutiger… - PLoS …, 2022 - journals.plos.org
Objective Low-level viraemia (LLV) occurs in some people with HIV (PWH) receiving
antiretroviral therapy (ART) and has been linked to inferior treatment outcomes. We …
antiretroviral therapy (ART) and has been linked to inferior treatment outcomes. We …